Optimal Treatment Strategy Based on for Pediatric AML

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (AML)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Cytarabine; Etoposide; Etoposide phosphate; Idarubicin; Mitoxantrone

Criteria

Inclusion Criteria:

• Patients who were newly diagnosed with de novo AML

• Patients who had recurrent cytogenetic abnormalities of AML even though the bone marrow blast percent is lower than 20%

Exclusion Criteria:

• Acute promyelocytic leukemia

• Down syndrome AML

• Therapy-related AML

• AML developed from myelodysplastic syndrome or other marrow failure syndrome

• Isolated myeloid sarcoma without bone marrow involvement

• Patients who cannot undergo chemotherapy as scheduled due to serious complications at diagnosis